Last updated on August 6th, 2026 at 03:05 pm
Last updated on August 6th, 2026 at 03:05 pm
The HILL Model: Treating Concussion Neuroinflammation with Low-Dose Lithium
Understanding the HILL Model: Head Impact, Concussions, Inflammation, and Nutritional Low-Dose Lithium for Prevention and Recovery
The HILL Model: Can Low-Dose Lithium Treat Concussions & Neuroinflammation?
Introduction: Rethinking Brain Injury, Prevention, and Recovery
The HILL Model: Rethinking Concussion Treatment with Low-Dose Lithium
Concussions and repetitive head impacts remain significant challenges across sports medicine, the military, and public health. While standard protocols focus on rest and symptom monitoring, they largely ignore the primary driver of secondary brain damage: neuroinflammation. A groundbreaking new framework, recently published in Trends Open, outlines the HILL model: Head impact, inflammation, low-dose lithium. This model proposes a radical shift from merely reacting to concussion symptoms to biologically modulating the brain’s response to trauma.
Understanding the Biological Impact of Concussions
Historically, traumatic brain injuries (TBIs) have been treated as purely mechanical insults. However, the HILL model reframes head impacts as dynamic, biologically modifiable events. The human brain is not evolved to withstand repetitive collision forces. Even subconcussive impacts—which athletes may endure hundreds of times per season—create shear forces that stretch axons and disrupt neuronal membranes. This mechanical stress triggers an immediate energy crisis and activates microglia (the brain’s immune cells). Over time, these activated cells create a feed-forward loop of chronic neuroinflammation, which is deeply linked to persistent post-concussive syndrome, cognitive decline, and Chronic Traumatic Encephalopathy (CTE).
Biomarkers: Tracking Brain Stress in Real-Time
To treat neuroinflammation, we must first measure it. Biomarkers, particularly inflammatory cytokines, act as quantifiable “vital signs” for the injured brain:
- IL-6: Rises sharply within hours of an impact, correlating with symptom severity.
- IL-1β: Amplifies the inflammatory wave and contributes to cell death.
- TNF-α: Bridges acute inflammation with long-term neurodegeneration.
By tracking these cytokines, medical professionals can map a patient’s physical exposure to their actual biological burden.
Introducing the HILL Framework
The HILL model directly links Head impacts (H) to Inflammation (I), and introduces Low-dose Lithium (LL) as a targeted, biological intervention to safely attenuate this process.
How Low-Dose Lithium Modulates Inflammation
While lithium is widely known as a high-dose psychiatric medication for bipolar disorder, it acts as a powerful neuroinflammatory modulator at “micro” or nutritional doses (1–20 mg of elemental lithium).
At these low levels, lithium works by:
- Inhibiting GSK-3β: Suppressing pro-inflammatory gene expression and reducing the release of harmful cytokines like IL-6 and TNF-α.
- Suppressing the NLRP3 Inflammasome: Blocking the molecular engine that drives cellular inflammation and pyroptosis (cell death).
- Stabilizing Mitochondria: Counteracting oxidative stress and promoting neuroplasticity and cellular repair.
Crucially, at these microdoses, lithium lacks the severe side effects and toxicity risks associated with standard psychiatric dosing, making it a viable candidate for widespread preventive use.
A New Era of Precision Concussion Management
If the HILL model is validated through clinical trials, it could revolutionize concussion protocols by introducing a tiered, biology-first approach to brain trauma.
Prophylactic Microdosing for High-Risk Groups
For contact athletes and military personnel, the model suggests daily nutritional microdosing (e.g., ~1 mg/day elemental lithium) as a form of biochemical preconditioning. This could lower baseline cytokine expression and raise the threshold at which mechanical forces trigger pathological inflammation.
Acute Treatment and Recovery Protocols
Following a significant head impact, the therapeutic window to prevent a prolonged inflammatory cascade is narrow. The model proposes:
- Acute Intervention: Administering a targeted low dose (10–30 mg/day) immediately after an impact to blunt the inevitable cytokine surge.
- Sustained Recovery: Continuing a low dose during the recovery window (e.g., 30–90 days) to help normalize immune signaling and prevent microglia from remaining in a “primed,” hyper-reactive state.
Future Directions for Brain Health
The HILL model argues that the long-term consequences of head impacts do not have to be an inevitable fate. By integrating wearable sensors to track impact forces, measuring blood-based inflammatory biomarkers, and utilizing low-dose lithium, sports medicine and public health systems can shift from simply managing concussion symptoms to actively building brain resilience.
About the Lead Researcher: Dr. Sudhir Gadh
Dr. Sudhir Gadh is a New York City-based psychiatrist and an affiliate researcher at the Karolinska Institute in Sweden and the Galicia Sur Health Research Institute in Spain. With a background as a commander in the U.S. Navy Medical Corps Reserve, his clinical and research work focuses on neuroinflammation, biomarker-driven psychiatry, and the role of low-dose lithium in mental health, neurodegeneration, and performance medicine. He is the principal investigator of the Karolinska Lithium-Inflammation Psychiatry (LIP) Study and a pioneer in integrating clinical practice with systems-level approaches to improve long-term brain resilience.
Read the Full Story
Interested in the deep science and the full proposed clinical implementations? Read the complete peer-reviewed article here: HILL model: Head impact, inflammation, low-dose lithium.